Trevena Inc (TRVN) Holdings Boosted by Bourgeon Capital Management LLC

Bourgeon Capital Management LLC raised its position in Trevena Inc (NASDAQ:TRVN) by 59.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 137,800 shares of the biopharmaceutical company’s stock after purchasing an additional 51,300 shares during the quarter. Bourgeon Capital Management LLC’s holdings in Trevena were worth $220,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in TRVN. Nationwide Fund Advisors boosted its position in Trevena by 92.1% in the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 23,557 shares in the last quarter. Alliancebernstein L.P. boosted its position in Trevena by 51.9% in the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 18,900 shares in the last quarter. American Century Companies Inc. acquired a new position in Trevena in the fourth quarter valued at about $135,000. Virtu KCG Holdings LLC boosted its position in Trevena by 144.0% in the second quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 34,618 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Trevena by 30.1% in the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 14,880 shares in the last quarter. Hedge funds and other institutional investors own 56.74% of the company’s stock.

Shares of Trevena Inc (NASDAQ TRVN) opened at $1.52 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92. The firm has a market cap of $90.74, a P/E ratio of -0.92 and a beta of -0.51. Trevena Inc has a 12 month low of $1.35 and a 12 month high of $8.00.

A number of equities analysts have weighed in on TRVN shares. Oppenheimer set a $5.00 target price on shares of Trevena and gave the stock a “buy” rating in a research note on Thursday, October 12th. HC Wainwright dropped their target price on shares of Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, October 12th. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research note on Saturday, January 20th. Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $15.00 to $2.50 in a research note on Monday, October 16th. Finally, Needham & Company LLC dropped their target price on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $7.35.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/06/trevena-inc-trvn-holdings-boosted-by-bourgeon-capital-management-llc.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding TRVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevena Inc (NASDAQ:TRVN).

Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit